Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer
- 1 April 2001
- Vol. 57 (4) , 46-51
- https://doi.org/10.1016/s0090-4295(00)00940-7
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Cancer statistics, 2000CA: A Cancer Journal for Clinicians, 2000
- A Nonsteroidal Anti-Inflammatory Drug, Flufenamic Acid, Inhibits the Expression of the Androgen Receptor in LNCaP CellsEndocrinology, 1999
- Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trialBritish Journal of Urology, 1998
- The C3(1)/SV40 T Antigen Transgenic Mouse Model of Prostate and Mammary CancerToxicologic Pathology, 1998
- Intake of Carotenoids and Retino in Relation to Risk of Prostate CancerJNCI Journal of the National Cancer Institute, 1995
- Design of the Prostate Cancer Prevention Trial (PCPT)Controlled Clinical Trials, 1995
- Mechanistic considerations in chemopreventive drug developmentJournal of Cellular Biochemistry, 1994
- Chemoprevention in prostate cancer: The role of difluoromethylornithine (DFMO)Journal of Cellular Biochemistry, 1992
- Prostatic intraepithelial neoplasia (PIN): Current conceptsJournal of Cellular Biochemistry, 1992
- Introductory remarks: Development of chemopreventive agents for prostate cancerJournal of Cellular Biochemistry, 1992